½ÃÀ庸°í¼­
»óǰÄÚµå
1525290

¼¼°èÀÇ ÀǾà ÁÂÁ¦ ½ÃÀå : ±Ô¸ðº°, À¯Çüº°, ±âÁ¦º°, ÃÖÁ¾ »ç¿ëÀÚº°, À¯Åë ä³Îº°, ó¹æ À¯Çüº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Pharmaceutical Suppositories Market Size Study, by Type, by Base, by End User, by Distribution Channel, by Prescription Type and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀǾà ÁÂÁ¦ ½ÃÀåÀº 2023³â¿¡ ¾à 16¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í ¿¹Ãø ±â°£ µ¿¾È 5.7% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀǾà ÁÂÁ¦Àº ÁÖ·Î Á÷Àå, Áú, ¿äµµ¿Í °°Àº ´Ù¾çÇÑ Ã¼°­¿¡ »ðÀÔÇϰí Åõ¿©ÇÏ´Â °íü ¶Ç´Â ¹Ý°íü Åõ¿© ÇüÅÂÀÔ´Ï´Ù. ÀÌ Á¾àÀº ü¿Â ¶Ç´Â ü¿Â ºÎ±Ù¿¡¼­ ÀÀ°íµÇ´Â ±âÀç¿Í °áÇÕµÈ ÀǾàǰ Ȱ¼º ¼ººÐ(API)À¸·Î ±¸¼ºµË´Ï´Ù. »ðÀԵǸé Á¾àÀº ¿ëÇØ, ¿ëÀ¶ ¶Ç´Â ºÐ»êµÇ¾î Á¡¸·°ú ±¹¼Ò Á¶Á÷À» ÅëÇØ Èí¼öµÇµµ·Ï ¾à¹°À» ¹æÃâÇÕ´Ï´Ù.

ÀǾà ÁÂÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ³ëÀÎ Àα¸ÀÇ È®´ë, ¸¸¼º,±Þ¼º Áúȯ Áõ°¡, Á¾à Á¦Á¶ÀÇ ±â¼ú Áøº¸¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ³ëÀÎÃþÀº Á¾Á¾ Ç¥ÀûÈ­µÈ ±¹¼Ò ¾à¹°Àü´ÞÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º ÁúȯÀ» ÀÏÀ¸Å°°í, Á¾àÀº È¿°úÀûÀÎ Ä¡·á ¹æ¹ýÀÌ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¿°Áõ¼º Àå Áúȯ, Ä¡Áú, Áú °¨¿°, ÅëÁõ °ü¸® µîÀÇ Áúº´Àº Á¾àÀ¸·Î ÀÎÇÑ ¾à¹° Àü´ÞÀÇ ÇýÅÃÀ» ¹Þ¾Æ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ±×·¯³ª ¾à¹° ÀûÇÕ¼ºÀÇ Á¦ÇѰú Á¦Á¶ º¹À⼺Àº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ¿¬±¸ Ȱµ¿ÀÇ È°¼ºÈ­¿Í ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ ½ÃÀåÀº ¼ºÀåÇϴ ż¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

Á¦¾à ÁÂ¾à ½ÃÀå Á¶»ç¿¡¼­ °í·ÁÇÑ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì ¹× ±âŸ ¶óƾ ¾Æ¸Þ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ÀǾà ÁÂÁ¦ ½ÃÀå¿¡¼­ ¼öÀ͸鿡¼­ Áö¹èÀûÀÎ Áö¿ªÀÔ´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº ±Þ¼ÓÇÑ ³ëÈ­, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ºñħ½ÀÀû ¾à¹° Àü´Þ ¹æ¹ý¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ¶ÇÇÑ Á¾à Á¦Á¦ÀÇ Áøº¸¿Í °ß°íÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ³ëÀÎ Àα¸ Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ÀÇ·áºñ Áõ°¡, Æí¸®Çϰí È¿°úÀûÀÎ ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ» ¹è°æÀ¸·Î ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¾à¹°Àü´Þ ¹æ¹ýÀ¸·Î¼­ Á¾àÀÇ ÀÎÁöµµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀǾà ÁÂÁ¦ ½ÃÀå ÁÖ¿ä ¿ä¾à

  • ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø(2022³â-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • À¯Çüº°
    • º£À̽ºº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • À¯Åë ä³Îº°
    • ó¹æ À¯Çüº°
  • ÁÖ¿ä µ¿Çâ
  • °æ±â ÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦2Àå ÀǾà ÁÂÁ¦ ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼úÀÇ Áøº¸
      • ȯ°æ¿¡ÀÇ ¹è·Á
      • ¼ÒºñÀÚÀÇ Àǽİú ¼ö¿ë
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó³âµµ
  • ȯÀ² º¯È¯À²

Á¦3Àå ÀǾà ÁÂÁ¦ ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ³ëÀÎ Àα¸ Áõ°¡
    • ¸¸¼º Áúȯ°ú ±Þ¼º Áúȯ Áõ°¡
    • ÁÂÁ¦ Á¦Á¶ÀÇ ±â¼úÀû Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ÇÑÁ¤µÈ ¾à¹° ÀûÇÕ¼º
    • Á¦Á¶ÀÇ º¹À⼺
  • ½ÃÀå ±âȸ
    • ¿¬±¸ Ȱµ¿ÀÇ È°¼ºÈ­
    • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç
    • Á¦³×¸¯ Á¾࿡ ´ëÇÑ ¼ö¿ä Áõ°¡

Á¦4Àå ÀǾà ÁÂÁ¦ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • Porter's Five Forces¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : À¯Çüº°(2022³â-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀǾà ÁÂÁ¦ ½ÃÀå À¯Çüº° ¼öÀÍ µ¿Ç⠺м®(2022³â,2032³â)
    • Á÷Àå¿ë ÁÂÁ¦
    • Áú¿ë ÁÂÁ¦
    • ¿äµµ¿ë ÁÂÁ¦

Á¦6Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ±âÁ¦º°(2022³â,2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀǾà ÁÂÁ¦ ½ÃÀå ±âÁ¦ ¼öÀÍ µ¿Ç⠺м®(2022³â,2032³â)
    • Áö¹æ¿°±â
    • ¼öȥȭ¼º ±âÁ¦
    • À¯È­¼º ±âÁ¦

Á¦7Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2022³â-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀǾà ÁÂÁ¦ ½ÃÀå ÃÖÁ¾ »ç¿ëÀÚ ¼öÀÍ µ¿Ç⠺м®(2022³â,2032³â)
    • º´¿ø ¹× Áø·á¼Ò
    • ÀçÅà °³È£
    • °³È£ ½Ã¼³

Á¦8Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : À¯Åë ä³Îº°(2022³â-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀǾà ÁÂÁ¦ ½ÃÀå À¯Åë ä³Îº° ¼öÀÍ µ¿Ç⠺м®(2022³â,2032³â)
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ ÆÇ¸Å

Á¦9Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : ó¹æ À¯Çüº°(2022³â,2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ÀǾà ÁÂÁ¦ ½ÃÀå ó¹æ À¯Çüº° ¼öÀÍ µ¿Ç⠺м®(2022³â,2032³â)
    • ÀϹݿë ÀǾàǰ
    • 󹿾à

Á¦10Àå ÀǾà ÁÂÁ¦ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°(2022³â-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Pfizer Inc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¸§)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Church & Dwight Co. Inc.
    • Viatris Inc.
    • Bliss GVS Pharma Ltd
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Cadila Healthcare Ltd
    • Intas Pharmaceuticals Ltd.
    • Sanofi SA
    • Bayer AG
    • Zydus Lifesciences Limited
    • AstraZeneca PLC
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson

Á¦12Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
BJH

Global Pharmaceutical Suppositories Market is valued approximately at USD 1.69 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.7% over the forecast period 2024-2032. Pharmaceutical suppositories are solid or semi-solid dosage forms that are inserted into various body cavities, primarily the rectum, vagina, or urethra, for delivering medication. These suppositories consist of active pharmaceutical ingredients (APIs) combined with a base material that solidifies at or near body temperature. Upon insertion, the suppository dissolves, melts, or disperses, releasing the medication for absorption through mucous membranes or local tissues.

The growth of the pharmaceutical suppositories market is primarily driven by the expanding geriatric population, the rise in chronic and acute diseases, and technological advancements in suppository manufacturing. The elderly population often develops chronic medical conditions that require targeted and localized drug delivery, making suppositories an effective treatment method. Moreover, conditions like inflammatory bowel disease, hemorrhoids, vaginal infections, and pain management benefit from suppository-based drug delivery, contributing to the market's growth. However, the limited drug compatibility and manufacturing complexities may impede market growth. Despite these challenges, the market is poised for growth due to increased research activities and the presence of key market players.

The key regions considered for the global Pharmaceutical Suppositories Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Pharmaceutical Suppositories Market in terms of revenue. The market growth in the region is being attributed to factors including rapidly aging population, increasing prevalence of chronic diseases, and a growing preference for non-invasive drug delivery methods. Additionally, advancements in suppository formulations and a robust healthcare infrastructure contribute to market growth. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising geriatric population, increasing prevalence of chronic diseases, growing healthcare expenditure, and the rising demand for convenient and effective drug delivery systems. Additionally, increasing awareness of suppositories as a drug delivery method is contributing to market growth.

Major market players included in this report are:

  • Pfizer Inc.
  • Church & Dwight Co. Inc.
  • Viatris Inc.
  • Bliss GVS Pharma Ltd
  • Glenmark Pharmaceuticals Limited
  • Novartis AG
  • Cadila Healthcare Ltd
  • Intas Pharmaceuticals Ltd.
  • Sanofi S.A.
  • Bayer AG
  • Zydus Lifesciences Limited
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson

The detailed segments and sub-segment of the market are explained below:

By Type:

  • Rectal Suppositories
  • Vaginal Suppositories
  • Urethral Suppositories

By Base:

  • Fatty Bases
  • Water Miscible Bases
  • Emulsifying Bases

By End User:

  • Hospitals and Clinics
  • Home Care
  • Nursing Home

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

By Prescription Type:

  • OTC
  • Prescribed Suppositories

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Pharmaceutical Suppositories Market Executive Summary

  • 1.1. Global Pharmaceutical Suppositories Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Type
    • 1.3.2. By Base
    • 1.3.3. By End User
    • 1.3.4. By Distribution Channel
    • 1.3.5. By Prescription Type
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Pharmaceutical Suppositories Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Pharmaceutical Suppositories Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rise in Geriatric Population
    • 3.1.2. Increase in Chronic and Acute Diseases
    • 3.1.3. Technological Advancements in Suppository Manufacturing
  • 3.2. Market Challenges
    • 3.2.1. Limited Drug Compatibility
    • 3.2.2. Manufacturing Complexities
  • 3.3. Market Opportunities
    • 3.3.1. Increasing Research Activities
    • 3.3.2. Presence of Key Market Players
    • 3.3.3. Growing Demand for Generic Suppositories

Chapter 4. Global Pharmaceutical Suppositories Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Pharmaceutical Suppositories Market Size & Forecasts by Type 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical Suppositories Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Rectal Suppositories
    • 5.2.2. Vaginal Suppositories
    • 5.2.3. Urethral Suppositories

Chapter 6. Global Pharmaceutical Suppositories Market Size & Forecasts by Base 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical Suppositories Market: Base Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Fatty Bases
    • 6.2.2. Water Miscible Bases
    • 6.2.3. Emulsifying Bases

Chapter 7. Global Pharmaceutical Suppositories Market Size & Forecasts by End User 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical Suppositories Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Hospitals and Clinics
    • 7.2.2. Home Care
    • 7.2.3. Nursing Home

Chapter 8. Global Pharmaceutical Suppositories Market Size & Forecasts by Distribution Channel 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global Pharmaceutical Suppositories Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Online Sales

Chapter 9. Global Pharmaceutical Suppositories Market Size & Forecasts by Prescription Type 2022-2032

  • 9.1. Segment Dashboard
  • 9.2. Global Pharmaceutical Suppositories Market: Prescription Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 9.2.1. OTC
    • 9.2.2. Prescribed Suppositories

Chapter 10. Global Pharmaceutical Suppositories Market Size & Forecasts by Region 2022-2032

  • 10.1. North America Pharmaceutical Suppositories Market
    • 10.1.1. U.S. Pharmaceutical Suppositories Market
      • 10.1.1.1. Type breakdown size & forecasts, 2022-2032
      • 10.1.1.2. Base breakdown size & forecasts, 2022-2032
      • 10.1.1.3. End User breakdown size & forecasts, 2022-2032
      • 10.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
      • 10.1.1.5. Prescription Type breakdown size & forecasts, 2022-2032
    • 10.1.2. Canada Pharmaceutical Suppositories Market
  • 10.2. Europe Pharmaceutical Suppositories Market
    • 10.2.1. U.K. Pharmaceutical Suppositories Market
    • 10.2.2. Germany Pharmaceutical Suppositories Market
    • 10.2.3. France Pharmaceutical Suppositories Market
    • 10.2.4. Spain Pharmaceutical Suppositories Market
    • 10.2.5. Italy Pharmaceutical Suppositories Market
    • 10.2.6. Rest of Europe Pharmaceutical Suppositories Market
  • 10.3. Asia-Pacific Pharmaceutical Suppositories Market
    • 10.3.1. China Pharmaceutical Suppositories Market
    • 10.3.2. India Pharmaceutical Suppositories Market
    • 10.3.3. Japan Pharmaceutical Suppositories Market
    • 10.3.4. Australia Pharmaceutical Suppositories Market
    • 10.3.5. South Korea Pharmaceutical Suppositories Market
    • 10.3.6. Rest of Asia Pacific Pharmaceutical Suppositories Market
  • 10.4. Latin America Pharmaceutical Suppositories Market
    • 10.4.1. Brazil Pharmaceutical Suppositories Market
    • 10.4.2. Mexico Pharmaceutical Suppositories Market
    • 10.4.3. Rest of Latin America Pharmaceutical Suppositories Market
  • 10.5. Middle East & Africa Pharmaceutical Suppositories Market
    • 10.5.1. Saudi Arabia Pharmaceutical Suppositories Market
    • 10.5.2. South Africa Pharmaceutical Suppositories Market
    • 10.5.3. Rest of Middle East & Africa Pharmaceutical Suppositories Market

Chapter 11. Competitive Intelligence

  • 11.1. Key Company SWOT Analysis
  • 11.2. Top Market Strategies
  • 11.3. Company Profiles
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Key Information
      • 11.3.1.2. Overview
      • 11.3.1.3. Financial (Subject to Data Availability)
      • 11.3.1.4. Product Summary
      • 11.3.1.5. Market Strategies
    • 11.3.2. Church & Dwight Co. Inc.
    • 11.3.3. Viatris Inc.
    • 11.3.4. Bliss GVS Pharma Ltd
    • 11.3.5. Glenmark Pharmaceuticals Limited
    • 11.3.6. Novartis AG
    • 11.3.7. Cadila Healthcare Ltd
    • 11.3.8. Intas Pharmaceuticals Ltd.
    • 11.3.9. Sanofi S.A.
    • 11.3.10. Bayer AG
    • 11.3.11. Zydus Lifesciences Limited
    • 11.3.12. AstraZeneca PLC
    • 11.3.13. Teva Pharmaceutical Industries Ltd.
    • 11.3.14. GlaxoSmithKline plc
    • 11.3.15. Johnson & Johnson

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦